Gene · 970
Papers4,349
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
781 to 800 of 4,349
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Nasopharyngeal carcinoma cells promote regulatory T cell development and suppressive activity via CD70-CD27 interaction. | Nat Commun | 2023 | 37024479 | PubTator, text mining | PubMed |
| The current landscape of CAR T-cell therapy for solid tumors: Mechanisms, research progress, challenges, and counterstrategies. | Front Immunol | 2023 | 37020537 | PubTator, text mining | PubMed |
| A novel transcriptional signature identifies T-cell infiltration in high-risk paediatric cancer. | Genome Med | 2023 | 37013636 | PubTator, text mining | PubMed |
| Clinical significance of nonerythrocytic spectrin Beta 1 (SPTBN1) in human kidney renal clear cell carcinoma and uveal melanoma: a study based on Pan-Cancer Analysis. | BMC Cancer | 2023 | 37013511 | PubTator, text mining | PubMed |
| Co-regulation of Sox9 and TGFβ1 transcription factors in mesenchymal stem cells regenerated the intervertebral disc degeneration. | Front Med (Lausanne) | 2023 | 37007782 | PubTator, text mining | PubMed |
| Healing mechanism of diabetic foot ulcers using single-cell RNA-sequencing. | Ann Transl Med | 2023 | 37007553 | PubTator, text mining | PubMed |
| Immunotherapy or targeted therapy: What will be the future treatment for anaplastic thyroid carcinoma? | Front Oncol | 2023 | 37007127 | PubTator, text mining | PubMed |
| Phosducin-like 3 is a novel prognostic and onco-immunological biomarker in glioma: A multi-omics analysis with experimental verification. | Front Immunol | 2023 | 37006287 | PubTator, text mining | PubMed |
| Precision targeted therapy for EGFR mutation-positive NSCLC: Dilemmas and coping strategies. | Thorac Cancer | 2023 | 37005552 | PubTator, text mining | PubMed |
| Aspartate beta-hydroxylase domain containing 1 as a prognostic marker associated with immune infiltration in skin cutaneous melanoma. | BMC Cancer | 2023 | 37004045 | PubTator, text mining | PubMed |
| New Presentation of CD27 Deficiency; Coronary Ectasia and COVID-19. | Iran J Allergy Asthma Immunol | 2023 | 37002625 | PubTator, text mining | PubMed |
| Protein phosphatase 2A propels follicular T helper cell development in lupus. | J Autoimmun | 2023 | 37001432 | PubTator, text mining | PubMed |
| AVPR2 is a potential prognostic biomarker and correlated with immune infiltration in head and neck squamous cell carcinoma. | BMC Med Genomics | 2023 | 36998036 | PubTator, text mining | PubMed |
| Preclinical development of a first-in-class vaccine encoding HER2, Brachyury and CD40L for antibody enhanced tumor eradication. | Sci Rep | 2023 | 36997583 | PubTator, text mining | PubMed |
| T cell co-stimulatory and co-inhibitory pathways in atopic dermatitis. | Front Immunol | 2023 | 36993982 | PubTator, text mining | PubMed |
| Chronic CD27-CD70 costimulation promotes type 1-specific polarization of effector Tregs. | Front Immunol | 2023 | 36993956 | PubTator, text mining | PubMed |
| A multiscale mechanistic model of human dendritic cells for in-silico investigation of immune responses and novel therapeutics discovery. | Front Immunol | 2023 | 36993954 | PubTator, text mining | PubMed |
| Toll-like Receptor-Mediated Immunomodulation of Th1-Type Response Stimulated by Recombinant Antigen of Type 2 Porcine Reproductive and Respiratory Syndrome Virus (PRRSV-2). | Viruses | 2023 | 36992483 | PubTator, text mining | PubMed |
| Evolution and Progress of mRNA Vaccines in the Treatment of Melanoma: Future Prospects. | Vaccines (Basel) | 2023 | 36992220 | PubTator, text mining | PubMed |
| Therapeutic Vaccination in Head and Neck Squamous Cell Carcinoma-A Review. | Vaccines (Basel) | 2023 | 36992219 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/970/papers?page=40